Q1 2025 Addex Therapeutics Ltd Earnings Call Transcript
Key Points
- Addex Therapeutics Ltd (ADXN) has made significant progress in its GABAB positive allosteric modulator program with partner Indivior, completing IND-enabling studies for substance use disorders.
- The company regained rights to its mGluR2 positive allosteric modulator program from Johnson & Johnson, opening new therapeutic opportunities.
- Addex Therapeutics Ltd (ADXN) has repositioned its mGluR5 negative allosteric modulator program for brain injury recovery, with promising preclinical data supporting its potential.
- The company has a strong cash position with CHF2.8 million, providing a runway through mid-2026, and has reduced cash burn following the Neurosterix spinout.
- Addex Therapeutics Ltd (ADXN) has a robust pipeline with multiple programs advancing, including a promising candidate for chronic cough with favorable preclinical efficacy and tolerability.
- The current cash position does not fund the progression of unpartnered programs into the clinic, indicating potential future financing needs.
- Revenue decreased compared to the previous year due to the completion of the funded research phase with Indivior, impacting financial performance.
- The company faces competition in the chronic cough market, with existing compounds showing promising efficacy but challenging tolerability profiles.
- There is uncertainty regarding the clinical development pathway and competitive landscape for the chronic cough program, which could impact future success.
- Addex Therapeutics Ltd (ADXN) needs to conduct further studies to optimize the use of dipraglurant in post-stroke rehabilitation, indicating a longer timeline before potential market entry.
Hello, everyone. I'd like to thank you all for attending our Q1 2025 financial results conference call. I'm here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D program.
I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today.
I will start this conference call by giving a quick overview of recent activities and achievements before reviewing our top line. I will then hand over to Misha who will review in more detail our mGluR5 negative allosteric modular program for brain injury recovery and our GABAB positive allosteric modulation preclinical program for cough. I will then review our Q1 2025 financial results. Following that, we will open the call for Q&A.
Moving on to the highlights. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
